Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150
Benzinga Newsdesk 4 weeks ago
Analyst RatingsNewsPrice Target
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.